ハイパルトロフィック心筋症候群の患者における心肺運動検査の長期的な予後値
Leopoldo Ordine1, Grazia Canciello1, Salvatore Di Napoli1
1Department of Advanced Biomedical Sciences, University of Naples 'Federico II', School of Medicine, Via S Pansini, 5, Naples I-80131, Italy.
ESC heart failure
|February 19, 2026
まとめ
心肺運動テスト (CPET) は,多動性心筋病 (HCM) の強力な予後ツールです. 酸素のピーク摂取量 (VO2) の減少は,無症状の患者でも,主要な不良心事 (MACE) を予測します.
科学分野:
- 心臓病学 心臓病学
- 運動生理学 運動生理学
背景:
- ハイパルトロフィック心筋病 (HCM) は,複雑な心筋疾患である.
- HCMにおける主要な不良心事 (MACE) の予測における心肺運動テスト (CPET) の予後的価値は,特に長期的な結果において,初期症状とは無関係に,さらなる明確化が必要である.
研究 の 目的:
- HCM患者のMACEに対するCPETの長期的な予測能力を評価する.
- CPETの調査結果が,ベースラインの症状とは無関係にリスクを階層化できるかどうかを判断する.
主な方法:
- 症状制限CPETを受けた154人のHCM患者を対象とした長期的研究.
- MACEには,隔膜縮小療法,終末期のHCM,突然の心臓死,心不全に関連する死亡または移植が含まれていました.
- 多変数および競合するリスクの分析は,平均12年間の追跡期間で実施されました.
主要な成果:
- 予測されたピークVO2 (PVO2%) <60%の割合の低下は,MACE (HR 4.16) の独立した予測因子でした.
- NYHA Class >Iはまた,MACE (HR 2.27) を予測した.
- 無症状 (NYHAクラスI) の患者では,PVO2%<60%がMACE (HR 5.611) の有意な予測因子であり,15年後にリスクが異なる.
結論:
- CPETは,HCM患者におけるリスク分層化のための強力な予後ツールです.
- 減少したピークVO2は,MACEのリスクの増加の重要な指標です.
- CPETは,無症状の個人を含むリスク評価を向上させることができます.
関連する概念動画
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...